News

Luminoah, Rivanna Medical selected to prestigious med-tech accelerator

Two Charlottesville startups have been selected to MedTech Innovator, a well-known accelerator for medical technology startups.

Luminoah and Rivanna Medical are among 65 companies selected for the Los Angeles-based accelerator’s 2025 cohort. They will participate in a four-month program geared toward accelerating a path to U.S. market success.

Luminoah and Rivanna were both selected in the diagnostic and monitoring category. Luminoah, a former Lighthouse Labs demo day winner that closed a $6 million Series A round in 2023, has developed a mobile feeding tube for patients that collects data. Rivanna offers four products using ultrasound-based imaging technology that it says offer better precision and efficiency to health care professionals.

The MedTech Innovator program will include access to MedTech Innovator’s ecosystem of manufacturers, investors, providers, patients and more. The accelerator’s alumni have collectively brought more than 400 products to market and raised roughly $10 billion in follow-on funding, according to MedTech Innovator.

The 65 selected companies will compete for a share of $800,000 in nondilutive funding. The winners will be selected by audience vote at industry conferences.

MedTech Innovator said it received nearly 1,500 applicants to the program. It ultimately invited 213 companies to pitch at road tour events in Los Angeles, Dublin and College Park, Maryland, and then whittled that field down to 65.

The cohort represents 13 countries and 17 U.S. states.

Read more here.

Recent News

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and

06/02/2026

Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development

Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, today announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. In conjunction with the closing of the Series B financing,

06/02/2026

GEN Names BioHealth Capital Region a Top 3 U.S. Biopharma Cluster for Fourth Year in a Row

The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., has once again been named one of the nation’s Top 3 biopharma clusters by Genetic Engineering & Biotechnology News (GEN), marking the region’s fourth consecutive year in the Top 3. GEN’s 2026 “Top 10 U.S. Biopharma Clusters” ranking was authored by Alex Philippidis, Senior Business